Ventyx Biosciences Inc (VTYX)
4.50
+0.06
(+1.35%)
USD |
NASDAQ |
May 09, 13:15
Ventyx Biosciences Free Cash Flow (Quarterly): -51.87M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -51.87M |
| September 30, 2023 | -34.71M |
| June 30, 2023 | -49.48M |
| March 31, 2023 | -30.98M |
| December 31, 2022 | -47.38M |
| September 30, 2022 | -24.09M |
| Date | Value |
|---|---|
| June 30, 2022 | -14.82M |
| March 31, 2022 | -12.76M |
| December 31, 2021 | -14.74M |
| September 30, 2021 | -11.24M |
| June 30, 2021 | -9.914M |
| March 31, 2021 | -3.019M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-51.87M
Minimum
Dec 2023
-3.019M
Maximum
Mar 2021
-25.42M
Average
-19.45M
Median
Free Cash Flow (Quarterly) Benchmarks
| Anavex Life Sciences Corp | -7.318M |
| CERo Therapeutics Holdings Inc | -- |
| Avinger Inc | -3.389M |
| Checkpoint Therapeutics Inc | -6.833M |
| RAPT Therapeutics Inc | -27.82M |